TD Cowen maintains Buy rating on Mirum Pharmaceuticals, $145 price target
TD Cowen kept a Buy rating on Mirum Pharmaceuticals with a $145 price target, implying a 70.4% upside from the Oct 20 close. The firm cited Mirum's strong pipeline, including Livmarli, and positive analyst sentiment as key factors.
How this was made
The 30-second read
Why it matters
The rating sustains positive sentiment but offers limited actionable insight.
Market read
Provides a modest bullish signal for MIRM but lacks a concrete catalyst for immediate trading.
What to watch
No new clinical data or regulatory events accompany the rating.
Background
Analyst note from TD Cowen reiterating a Buy stance and issuing a $145 price target for Mirum Pharmaceuticals.
Ticker impact
TD Cowen maintained a Buy rating and set a new $145 price target for Mirum Pharmaceuticals.
potential upward pressure as investors price in the higher target.
Buy rating and 70% upside target suggest optimism, but no new catalyst beyond the rating.
Market effects
May lift sentiment in the rare‑disease biotech niche.
Limited to US biotech investors.
Low
Counterpoint
Target may be overly optimistic without fresh data; price could stall.
Key entities
- CompanyMirum Pharmaceuticals
Biotech firm focused on rare‑disease therapies.
- AnalystTD Cowen
Equity research firm providing the rating and target.